Voyager Therapeutics Inc (VYGR) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was...

Form 8-K - Current report

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a...

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional...

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities